Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study

Authors

  • T. L. Monte,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • 1 C. R. M. Rieder,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • 1 A. B. Tort,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • 1 I. Rockenback,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • 1 M. L. Pereira,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • 2,4 I. Silveira,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • 5 A. Ferro,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • 5 J. Sequeiros,

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • and 5 L. B. Jardim 2,3

    1. 1 Neurology; and 2 Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Brazil; 3 Departments of Internal Medicine; and 4 Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Algre, Brazil; and 5UniGENe, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Search for more papers by this author

Laura B. Jardim, Hospital de Clínicas de Porto Alegre – Serviço de Genética, Rua Ramiro Barcelos 2350, 90035-003, Porto Alegre, Brazil
Tel.: +51 3316 8620
Fax: +55 (51) 33168678
e-mail: laurajardim@terra.com.br

Abstract

Context – Machado-Joseph Disease (MJD/SCA3) is an autosomal dominant spinocerebellar degeneration that evolves to disability and death. Experimental data have shown that serotonin is an important cerebellar neurotransmitter and that impairment of the serotoninergic cerebellar system can induce cerebellar ataxia.

Objectives – To evaluate the efficacy of fluoxetine, a serotonin reuptake inhibitor, in treating neurologic dysfunction in patients with MJD.

Patients and methods – Thirteen MJD patients were treated with fluoxetine (20 mg/day) and were followed-up for 6 weeks. Outcome measures included functional capacity, standardized neurologic and cognitive ratings. The Montgomery-Asberg depression rating scale was used to control depressive symptoms.

Results – There was no significant improvement in motor abilities after 6 weeks of treatment.

Conclusions – These results suggest that fluoxetine has no benefit in motor function of patients with MJD/SCA3.

Ancillary